

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

UGOEAVDCAT: Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel

UGOEAVDPNC: Alternative Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin

Gastrointestinal Protocol Optimization – Phase 2 BC Cancer Serious Adverse Drug Reaction (ADR) Documentation and Reporting Protocol

Cancer Drug Manual®

New: Mirvetuximab Soravtansine, Retifanlimab

Revised: Dostarlimab, Isatuximab, Nelarabine

Chemotherapy Preparation and Stability Chart:

Datopotomab Deruxtecan, Methotrexate, Mirvetuximab Soravtansine retifanlimab

Extravasation Hazard Table: Nelarabine

Continuing Education

Family Practice Oncology Network

Benefit Drug List

New: UGOEAVDCAT, UGOEAVDPNC, nelarabine (pediatric)

Deleted: GOENDCAT

REVISED Protocols, PPOs and Patient Handouts

BR BRAVSG **CN** CNTEMOZMD **GI** GIAJCAPOX, GIAJFFOX, GIAJFL, GIAJRALOX, GIAVCAPB, GIAVCETIR, GIAVFL, GIAVPG, GIAVRALIR, GIAVRALOX, GIAVTZCAP, GIBAJCAP, GICAPIRI, GICAPOX, GICIRB, GICOXB, GIEFFOXRT, GIFFIRB, GIFFIRPAN, GIFFOXB, GIFFOXPAN, GIFIRINOX, GIFOLFIRI, GIFOLFOX, GIGAJCOX, GIGAJFFOX, GIGAVCFT, GIGAVCOX, GIGAVCOXN, GIGAVCOXP, GIGAVCOXT, GIGAVFFOX, GIGAVFFOXN, GIGAVFFOXP, GIGAVFFOXT, GIGAVPCOXT, GIGAVPFOXT, GIGAVRAMT, GIGFLODOC, GIGOLFIRI, GIIR, GIIRINALT, GIPAJFIROX, GIPAJGCAP, GIPAJGEM, GIPAVFFIRI, GIPAVFFOX, GIPGEM, GIPGEMABR, GIRAJCOX, GIRAJFFOX, GIRCAP **GO** GOCISP, GOCXCAT, GOENDAJCAT, GOENDAVCAT **HN** HNNLAPG **LU** LUPUPE, LUSCPE, LUSCPI **MY** UMYISACARD, UMYISAPOMD **SC** SCIMMUNE

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 February 2025. Full details of all treatment programs are available in the Chemotherapy Protocols section of the BC Cancer website.

Gynecologic

Dostarlimab for Treatment of Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel (UGOEAVDCAT and UGOEAVDPNC) – The BC Cancer Gynecologic Tumour Group is introducing dostarlimab in combination with carboplatin and paclitaxel as a new treatment option for patients with primary advanced or recurrent MSI-H or dMMR endometrial cancer. Patients are eligible if they have not received prior systemic treatment in the advanced setting or experience a recurrence a minimum of 6 months after prior treatment in the

Editor's Choice

neoadjuvant or adjuvant setting. Dostarlimab is a humanized IgG4 monoclonal antibody immune checkpoint inhibitor that binds to programmed death receptor-1 (PD-1) on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. The BC Cancer Gynecologic Tumour Group is also implementing an alternative treatment protocol utilizing a paclitaxel-NAB chemotherapy backbone, for patients with previous severe hypersensitivity reaction or anaphylaxis to paclitaxel that is not manageable despite use of premedications.

Use of these treatments is supported by evidence from the phase III, double-blind, placebo-controlled RUBY Part 1 trial. The trial demonstrated that dostarlimab in combination with carboplatin and paclitaxel significantly increased progression-free survival in patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer. Dostarlimab is associated with manageable toxicities consistent with similar immune checkpoint inhibitors.

BC Cancer Compassionate Access Program (CAP) approval is required prior to treatment.

References:

1. Mirza MR, Chase DM, Slomovitz BM, et al: RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. *N Engl J Med.* 2023 Jun 8;388(23):2145-2158.
2. Dostarlimab (Jemperli) CADTH [Canada's Drug Agency (CDA-AMC)] Reimbursement Recommendation. *Canadian Journal of Health Technologies* May 2024; 4(5): 1-25.

Gastrointestinal Protocols Optimization – Phase 2

The Gastrointestinal (GI) Tumour Group has completed the final phase of the GI protocol optimization work. The following represent notable changes being implemented on 01 Feb 2025.

Deselection of Fluorouracil IV Push (Bolus) and Leucovorin in Advanced Protocols

Fluorouracil IV push (bolus) and leucovorin will be optional orders for patients receiving treatment in the advanced setting. This change is supported by recent evidence that demonstrates a reduction in toxicity without a corresponding decrease in overall survival outcomes. These orders will no longer be preselected in preprinted orders and Cerner PowerPlans. Prescribers wishing to retain fluorouracil bolus and leucovorin can still select these options when prescribing, allowing for personalized care based on patient-specific needs and clinical judgment.

There will be no change to the prescribing practice for patients being treated with curative intent. Providers should continue to initiate treatment with fluorouracil IV push and leucovorin as part of the standard regimen, as currently practiced.

Optional Leucovorin IV Push

Historically, leucovorin has been administered as a 2-hour IV infusion. In line with evolving practices, we are now offering an optional leucovorin IV push across all GI treatment protocols, including adjuvant settings. This flexibility allows for improved efficiency and convenience, particularly in cases where IV fluorouracil, oxaliplatin or irinotecan is omitted. This update aims to streamline treatment delivery without compromising efficacy.

Editor's Choice

Addition of Concurrent D5W for Oxaliplatin-Induced Vascular Pain

To address the issue of vascular pain commonly experienced by patients receiving oxaliplatin via peripheral lines, protocols have been updated to include 5% dextrose in water (D5W) administration concurrently with oxaliplatin. Recent feedback from providers indicates that D5W is routinely used to mitigate this side effect in the majority of cases. As a result, D5W will now be preselected for patients receiving oxaliplatin.

However, providers can deselect this option if additional fluid intake is not indicated, such as in patients with central lines or when there are concerns about fluid overload.

PD-L1 Requirement for Metastatic Upper GI Protocols

A new eligibility PD-L1 status requirement was incorporated for treatment protocols involving combination immunotherapy and chemotherapy for treatment of metastatic upper GI malignancies, GIGAVCOXN, GIGAVFFOXN, GIGAVCOXP, and GIGAVFFOXP.

Recent data reviews have shown that the benefit of such combination treatment is limited to patients with PD-L1 positive status. In light of these findings, PD-L1 testing and positive result is now a prerequisite for patients undergoing treatment with above mentioned protocols. This update ensures that immunotherapy is appropriately administered to those most likely to benefit, aligning with the latest clinical guidelines and supporting responsible, evidence-based stewardship in treatment decision-making.

Patients who are already undergoing treatment with these regimens but do not meet the new requirement may continue their current course of treatment in consultation with their provider.

BC Cancer Serious Adverse Drug Reaction (ADR) Documentation and Reporting Protocol

All documented serious adverse drug reactions (ADRs) must be reported to Health Canada in accordance with Canada's Food and Drugs Act and the Food and Drug Regulations.

As cancer treatments have narrow therapeutic indices, many cancer patients experience ADRs. The new BC Cancer Serious Adverse Drug Reaction (ADR) Documentation and Reporting Protocol, which will be posted on SHOP on Feb 1, defines:

- how ADRs should be documented in health record.
- the conditions when serious oncology ADRs need to be reported to Health Canada.

This Protocol must be used along with the PHSA [Patient Safety Policy](#) and [PHSA Serious Adverse Drug Reaction: Reporting to Health Canada Document](#) for the overarching serious ADR reporting process.

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Chemotherapy Preparation and Stability Chart entry is made available for reference only.

The **Mirvetuximab soravtansine Interim Monograph** has been developed. **Mirvetuximab soravtansine** is an antibody-drug conjugate (ADC) composed of an IgG anti-FR α monoclonal antibody linked to a maytansoid antitubulin agent (DM4) via a cleavable linker. **Mirvetuximab soravtansine** is used as monotherapy in the treatment of FR α positive ovarian cancer. The usual dose is 6 mg/kg (using an adjusted ideal body weight) given IV once every three weeks.

Highlights from these documents include:

- ocular adverse events are common, including corneal events; lubricating eye drops are recommended throughout treatment, but steroid eye drops may also be required for the management of keratopathy
- peripheral neuropathy is reported in approximately one-third of patients
- antiemetics and premedication with corticosteroid, antihistamine, and antipyretic are recommended with each infusion

Mirvetuximab soravtansine has been added to the **Chemotherapy Preparation and Stability Chart**, and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

The **Retifanlimab Interim Monograph** has been developed. **Retifanlimab** is a programmed death receptor-1 (PD-1) checkpoint inhibitor used in the treatment of Merkel cell carcinoma. The usual dose is a fixed dose of 500 mg given intravenously once every 4 weeks. Retifanlimab is only available via the Health Canada Special Access Program.

Highlights from these documents include:

- immune-mediated adverse events are managed with treatment interruption and corticosteroids; refer to treatment protocol and/or SCIMMUNE for details
- infusion-related reactions are rare, but can be severe; consider premedication in patients with prior infusion-related reactions
- dose reductions are not recommended

Retifanlimab has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Isatuximab Monograph

<i>Parenteral Administration table:</i>	Added 30 minutes to range for infusion duration to align with protocols UMYISACARD and UMYISAPOMD
---	---

Nelarabine Monograph and Patient Handout

<i>Header/Footer:</i>	Removed interim designation
<i>Patient Handout:</i>	Removed interim designation

Chemotherapy Preparation and Stability Chart

<i>Datopotomab deruxtecan:</i>	revised suggested bag volume in product column
<i>Methotrexate:</i>	Added Fresenius Kabi 1 g vial (authorized US brand to address an ongoing drug shortage situation)
<i>Mirvetuximab soravtansine:</i>	Added to chart
<i>Retifanlimab:</i>	Added to chart

User's Guide

<i>Interactions:</i>	revised information pertaining to drug-food, drug-herbal, and drug-lab interactions
----------------------	---

Extravasation Hazard Table

<i>Nelarabine:</i>	Added to table under 'none'
--------------------	-----------------------------

Continuing Education

Family Practice Oncology Network

The Family Practice Oncology Network (FPON) is pleased to announce a webinar session on Thyroid Cancer: What Family Physicians Need to Know When Caring for Their Patients with Dr. Shivraj Riar, on Thursday 20 February 2025, from 8 to 9 am, as part of the Complimentary Accredited Webinar Series.

The session will cover:

- Approach to assessment of a thyroid nodule
- Diagnostic process
- Post-thyroid cancer treatment surveillance recommendations
- Primary care provider's role in TSH monitoring and management with thyroid suppressive medication

For more information and link to registration, visit:

<https://ubccpd.ca/learn/learning-activities/course?eventtemplate=903-fpon-webinar-thyroid-cancer-what-family-physicians-need-to-know-when-caring-for-their-patients>

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 February 2025:

Protocol Title	Protocol Code	Benefit Status
Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel	UGOEAVDCAT	Restricted
Alternative Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin	UGOEAVDPNC	Restricted
Nelarabine for addition to front-line multi-agent therapy of pediatric, adolescent, and young adult patients with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL)	Pediatric	Class I

Deleted Programs

The following programs have been deleted from the BC Cancer [Benefit Drug List](#) effective 01 February 2025:

Protocol Title	Protocol Code	Benefit Status
Treatment of Primary Advanced or Recurrent Endometrial Cancer using Carboplatin and Paclitaxel	GOENDCAT	Class I

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAVSG	Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab Govitecan	<i>Precautions updated</i>	<i>Atropine orders clarified</i>	--
CN Neuro-Oncology				
CNTEMOZMD	Therapy for Malignant Brain Tumours using Metronomic Dosing of Temozolomide	<i>Tests, dose modifications and precautions updated</i>	<i>Prechemo metrics and tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GI Gastrointestinal				
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin and Capecitabine	<i>Exclusions, premedications, and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected</i>	--
GIAJFFOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Leucovorin IV push option added, exclusions, premedications, treatment, dose modifications and precautions updated</i>	<i>Premedications updated, leucovorin IV push added</i>	--
GIAJFL	Adjuvant Therapy of Colon Cancer using Fluorouracil and Leucovorin	<i>Leucovorin IV push option added, title and dose modifications updated, exclusion removed</i>	<i>Leucovorin IV push option added</i>	--
GIAJRALOX	Adjuvant Combination Chemotherapy for Node Positive Colon Cancer Using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>Premedications, treatment, precautions, and references updated</i>	<i>Premedications updated, D5W for vascular pain added</i>	--
GIAVCAPB	Palliative Therapy of Metastatic Colorectal Cancer using Capecitabine and Bevacizumab	<i>Eligibility, exclusions, and references updated</i>	--	--
GIAVCETIR	Third Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan	<i>Dose modifications and precautions updated</i>	<i>Atropine orders clarified</i>	--
GIAVFL	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Fluorouracil and Leucovorin	<i>Title, treatment, and dose modifications updated, exclusion removed, references added</i>	<i>Fluorouracil IV push optional</i>	--
GIAVPG	First-line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and Platinum	<i>Tests updated</i>	<i>Tests updated</i>	--
GIAVRALIR	Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>Precautions updated</i>	<i>Atropine orders clarified</i>	--
GIAVRALOX	Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>Premedications and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected</i>	--
GIAVTZCAP	Palliative Therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine	<i>Cautions updated</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GIBAJCAP	Adjuvant Therapy of Biliary Cancer using Capecitabine	<i>Cautions updated</i>	--	--
GICAPIRI	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Irinotecan and Capecitabine in Patients Unsuited for GIFOLFIRI	<i>Title, eligibility, exclusions, and precautions updated</i>	<i>Atropine orders clarified</i>	--
GICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Oxaliplatin and Capecitabine	<i>Premedications and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected, hypersensitivity banner added</i>	--
GICIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Bevacizumab and Capecitabine	<i>Eligibility, exclusions, precautions and references updated</i>	<i>Atropine orders clarified</i>	--
GICOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Bevacizumab and Capecitabine	<i>Eligibility, exclusions, premedications, precautions and references updated</i>	<i>Premedications updated, D5W for vascular pain preselected, hypersensitivity banner added</i>	--
GIEFFOXRT	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy	<i>Exclusions, premedications, and precautions updated</i>	<i>Premedications updated, hypersensitivity banner added</i>	--
GIFFIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin, and Bevacizumab	<i>Eligibility, exclusions, treatment, dose modifications, precautions and references updated</i>	<i>Leucovorin and fluorouracil optional, atropine orders clarified</i>	--
GIFFIRPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin, and Panitumumab	<i>Eligibility, exclusions, treatment, dose modifications, precautions and references updated</i>	<i>Fluorouracil IV push optional, atropine orders clarified</i>	--
GIFFOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Bevacizumab	<i>Eligibility, exclusions, premedications, treatment, dose modifications, precautions, and references updated</i>	<i>Premedications updated, leucovorin and fluorouracil IV push optional, hypersensitivity banner added</i>	--
GIFFOXPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Panitumumab	<i>Eligibility, exclusions, premedications, treatment, dose modifications, precautions, and references updated</i>	<i>Premedications updated, fluorouracil IV push optional</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GIFIRINOX	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility clarified, exclusions, cautions, tests, premedications, treatment, dose modifications, precautions and references updated</i>	<i>Premedications and tests updated, leucovorin IV push added, fluorouracil IV push optional, atropine orders clarified</i>	--
GIFOLFIRI	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil and Leucovorin	<i>Exclusion removed, treatment, dose modifications, precautions and references updated</i>	<i>Leucovorin and fluorouracil IV push optional, atropine orders clarified</i>	--
GIFOLFOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Exclusions, premedications, treatment, dose modifications, precautions, and references updated</i>	<i>Premedications updated, leucovorin and fluorouracil IV push optional</i>	--
GIGAJCOX	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin and Capecitabine	<i>Exclusions, premedications, and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected, hypersensitivity banner added</i>	--
GIGAJFOX	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Exclusions, premedications, treatment, dose modifications and precautions updated</i>	<i>Premedications updated, leucovorin IV push added</i>	--
GIGAVCFT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using Cisplatin, Capecitabine and Trastuzumab	--	<i>Reformatted, hypersensitivity banner added</i>	--
GIGAVCOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Carcinoma using Capecitabine, and Oxaliplatin	<i>Exclusions, cautions, premedications, and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected, hypersensitivity banner added</i>	--
GIGAVCOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	<i>Eligibility, exclusions, premedications, precautions and references updated</i>	<i>Premedications updated, D5W for vascular pain preselected, volume of oxaliplatin D5W flush removed</i>	--

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol Title	Protocol	PPPO	Handout
GIGAVCOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	<i>Eligibility, exclusions, premedications, treatment, precautions, and references updated</i>	<i>Premedications updated, D5W for vascular pain preselected, volume of oxaliplatin D5W flush removed</i>	--
GIGAVCOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin, and Trastuzumab	<i>Exclusions, cautions, premedications, treatment, and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected, hypersensitivity banner added</i>	--
GIGAVFFOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	<i>Exclusions, cautions, premedications, treatment, dose modifications, precautions, and references updated</i>	<i>Premedications updated, leucovorin and fluorouracil IV push optional</i>	--
GIGAVFFOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	<i>Eligibility, exclusions, premedications, treatment, dose modifications, precautions and references updated</i>	<i>Premedications updated, leucovorin and fluorouracil IV push optional, volume of oxaliplatin D5W flush removed</i>	--
GIGAVFFOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	<i>Eligibility, exclusions, treatment, dose modifications and references updated</i>	<i>Premedications updated, leucovorin and fluorouracil IV push optional, volume of oxaliplatin D5W flush removed</i>	--
GIGAVFFOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab	<i>Exclusions, cautions, premedications, treatment, dose modifications, precautions, and references updated</i>	<i>Premedications updated, leucovorin and fluorouracil IV push optional and hypersensitivity banner added</i>	--
GIGAVPCOXT	Treatment of Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin, and Trastuzumab	<i>Exclusions, premedications, and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GIGAVPFOXT	Treatment of Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab	<i>Exclusions, premedications, treatment, dose modifications, precautions and references updated</i>	<i>Premedications updated, leucovorin and fluorouracil IV push optional</i>	--
GIGAVRAMT	Second-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer using Weekly Paclitaxel and Ramucirumab	<i>Premedications clarified</i>	--	--
GIGFLODOC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Docetaxel, Oxaliplatin, Infusional Fluorouracil, and Leucovorin	<i>Exclusions, cautions, premedications, and precautions updated, treatment clarified</i>	<i>Premedications updated</i>	--
GIGFOLFIRI	Second or Third Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma or Esophageal Squamous Cell Carcinoma using Irinotecan, Fluorouracil and Leucovorin	<i>Cautions, treatment, dose modifications, precautions and references updated, exclusion removed</i>	<i>Leucovorin IV push added, leucovorin and fluorouracil optional, atropine orders clarified</i>	--
GIIR	Palliative Chemotherapy of Metastatic Colorectal Cancer using Irinotecan	<i>Precautions updated</i>	<i>Atropine orders clarified</i>	--
GIRINALT	Palliative Chemotherapy of Metastatic Colorectal Cancer using Weekly Irinotecan	<i>Precautions updated</i>	<i>Atropine orders clarified</i>	--
GIPAJFIROX	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility clarified, exclusions, cautions, premedications, tests, treatment, dose modifications and precautions updated</i>	<i>Premedications and tests updated, leucovorin IV push added, atropine orders clarified</i>	--
GIPAJGCAP	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Capecitabine and Gemcitabine	<i>Tests updated</i>	<i>Tests updated</i>	--
GIPAJGEM	Adjuvant Chemotherapy for Pancreatic Adenocarcinoma Using Gemcitabine	<i>Tests updated</i>	<i>Tests updated</i>	--
GIPAVFFIRI	Treatment of Metastatic Pancreatic or Biliary Tract Cancer using Irinotecan, Fluorouracil and Leucovorin	<i>Title, eligibility, tests, cautions, treatment, dose modifications, precautions and references updated. Exclusion removed</i>	<i>Leucovorin and fluorouracil IV push optional, atropine orders clarified, tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GIPAVFFOX	Palliative Combination Chemotherapy for Metastatic Pancreatic or Biliary Tract Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Exclusions, cautions, tests, premedications, treatment, dose modifications, precautions and references updated</i>	<i>Premedications and tests updated, leucovorin and fluorouracil IV push optional</i>	--
GIPGEM	Palliative Chemotherapy for Pancreatic Adenocarcinoma, Gallbladder Cancer, and Cholangiocarcinoma Using Gemcitabine	<i>Tests updated</i>	<i>Tests updated</i>	--
GIPGEMABR	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with Paclitaxel NAB (ABRAXANE) and Gemcitabine	<i>Tests updated</i>	<i>Tests updated</i>	--
GIRAJCOX	Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	<i>Exclusions, premedications and precautions updated</i>	<i>Premedications updated, D5W for vascular pain preselected, hypersensitivity banner added</i>	--
GIRAJFFOX	Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Exclusions, premedications, treatment, dose modifications and precautions updated</i>	<i>Premedications updated, and hypersensitivity banner added</i>	--
GIRCAP	Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation Therapy Alone	<i>Treatment updated</i>	--	--
GO Gynecologic				
GOCISP	Alternative Treatment of Gynecological Malignancies using Cisplatin and Paclitaxel	<i>Eligibility updated</i>	--	--
GOCXCAT	Primary Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with Carboplatin and Paclitaxel in Ambulatory Care Settings	<i>Tests updated</i>	--	--
GOENDAJCAT	Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using Carboplatin and Paclitaxel	<i>Tests and treatment section updated</i>	<i>Tests updated</i>	--
GOENDAVCAT	Treatment of Advanced or Recurrent Endometrial Cancer using Carboplatin and Paclitaxel	<i>Tests and treatment section updated</i>	<i>Tests updated</i>	--
HN Head and Neck				
HNNLAPG	Induction Treatment of Locally Advanced Nasopharyngeal Cancer with Cisplatin and Gemcitabine	<i>Tests clarified, gemcitabine dose reduced, precautions and references updated</i>	<i>Gemcitabine dose and tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LU Lung				
LUPUPE	Treatment of Cancer of Unknown Primary Involving the Thorax with Cisplatin and Etoposide	<i>Treatment duration extended</i>	--	--
LUSCPE	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide	<i>Eligibility updated</i>	--	--
LUSCPI	Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan With or Without Platinum	<i>Precautions updated</i>	<i>Atropine orders clarified</i>	--
MY Myeloma				
UMYISACARD	Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Premedications, isatuximab infusion duration, vitals monitoring and appendix updated)</i>	<i>Premedications and isatuximab infusion duration updated, vital signs and observation requirements updated</i>	--
UMYISAPOMD	Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Premedications, isatuximab infusion duration, vitals monitoring, and appendix updated</i>	<i>Premeds, isatuximab infusion duration, vital signs and observation requirements updated</i>	--
SC Supportive Care				
SCIMMUNE	Management of Immune-Mediated Adverse Reactions to Checkpoint Inhibitor Immunotherapy	<i>Eligibility, footer and references updated</i>	--	<i>Dostarlimab and tremelimumab examples added</i>

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor Pharmacy Oncology Certification	604-877-6275 250-519-5500 x 693742 250-712-3900 x 686820	druginfo@bccancer.bc.ca nbadry@bccancer.bc.ca rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@phsa.ca ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford BC Cancer – Kelowna BC Cancer – Prince George BC Cancer – Surrey BC Cancer – Vancouver BC Cancer – Victoria	604-851-4710 250-712-3900 250-645-7300 604-930-2098 604-877-6000 250-519-5500	toll free 877-547-3777 toll free 888-563-7773 toll free 855-775-7300 toll free 800-523-2885 toll free 800-663-3333 toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
Jelena Mucovic, BScPharm (Assistant Editor)
Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
Alison Pow, BScPharm
Yuna Jang, RN